Platform designed to cut cell and gene therapy production costs attracts €6.9 million for UK startup Tozaro

**European Biotech Innovation Sees Significant Funding Surge for Cell and Gene Therapy Advancement** European biotechnology continues its strong trajectory with a notable €6.9 million funding round for UK-based Tozaro, a company poised to revolutionize cell and gene therapy production. This investment, led by Mercia Ventures, will bolster Tozaro's mission to reduce the prohibitive costs associated with these life-saving treatments, potentially unlocking wider patient access to groundbreaking therapies. The funding underscores growing investor confidence in innovative platform technologies addressing critical manufacturing bottlenecks within the advanced therapeutics sector. Tozaro's proprietary "Smart Polymer" technology utilizes a vast array of over 500 chemical groups, far exceeding the limited 20 amino acids used in traditional protein and peptide-based methods. This approach allows for highly specific binding to gene therapy vectors, dramatically improving manufacturing yields and quality while simultaneously slashing production costs. This technological leap is crucial, given that advanced therapies like CAR-T treatments can cost upwards of €425,000 per patient, and gene therapies for rare genetic diseases can exceed €1.1 million, creating significant access barriers. The impact of this funding extends beyond Tozaro, highlighting a broader European trend. Adjacent funding rounds in 2025, including EpilepsyGTx’s €28 million Series A, Fuse Vectors' €4.9 million pre-Seed, and BOOST Pharma's €3.1 million, collectively represent over €36 million invested in cell and gene therapy innovation across the UK and Denmark. These investments demonstrate a concentrated effort to address both manufacturing scalability and clinical development, signaling a robust ecosystem dedicated to advancing next-generation medical treatments within Europe.